Immunoglobulin A (IgA) nephropathy is a condition that causes a certain type of protein to build up in your kidneys. It progresses differently in everyone. Your kidneys might still work well years ...

IgA nephropathy is progressive. That means it gets worse the longer you have it. It's not curable, but treatments can slow kidney damage and keep these organs working longer. It's important to ...

Immunoglobulin A nephropathy (also known as IgA nephropathy or Berger's disease) is a condition that causes IgA antibodies to accumulate in the kidneys—leading to damage that affects their blood ...

Andrew S. Bomback, MD, MPH, comments on the impact of disparities in diagnosing and treating IgA nephropathy by nephrologists. Early detection and treatment of IgA nephropathy are critical for ...

Acquired In-Process Research and Development expense: Acquired in-process research and development expense was $51.7 million for the full year ended December 31, 2024 relating to the Company’s ...

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythem ...

FDA Clearance of budoprutug IND in ITP. The Company received clearance ... antibody for IgAN and other B-cell mediated diseases. IgA nephropathy (IgAN): IgAN is an autoantibody mediated disease ...

Our cornerstone asset, budoprutug, a potentially best-in-class anti-CD19 monoclonal antibody, is being developed for three initial indications: pMN, ITP, and SLE, each of which represents a ...